The COMPPARE Coordinating Center announced today that the study has enrolled its 1,500th proton prostate cancer patient and has closed enrollment for the proton cohort. This goal was achieved in advance of the projected completion date of July 31, 2022. The proton cohort is divided into two groups: Pragmatic and…
The COMPPARE Coordinating Center announced today that the study achieved 75% enrollment on May 3, 2022. COMPPARE realized both a remarkable overall accrual rate and a exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. In fact, the study stands to become a model for patient-centric clinical…
Brotherhood of the Balloon, a COMPPARE Partner Organization, reports on a new technology known as theranostics in the latest BOBtales newsletter. This approach combines molecular therapies (therapy) and paired molecular targeted imaging (diagnostics). In theranostics, a special diagnostic molecule is first…
Dear COMPPARE team, participants, stakeholders and friends, I am pleased to announce that on December 14, 2021 Hampton University Proton Therapy Institute enrolled our 2,000th COMPPARE participant! This means we are now two-thirds of the way through with accrual, an exceptional accomplishment given the ongoing challenges presented by COVID-19. …
A Message from Dr. Nancy Mendenhall Our focus on IMRT enrollment has increased as we have become more aware of practice pattern changes that have impacted IMRT accrual, specifically the increased utilization of ultra-hypofractionated radiation (stereotactic body radiation therapy, or SBRT). Read Dr. Mendenhall’s message.
Researchers at the University of California San Diego School of Medicine have validated a more comprehensive genetic tool for predicting age of onset of aggressive prostate cancer. Brotherhood of the Balloon, a COMPPARE Partner Organization, told their BOB Tales summer newsletter…
Dear COMPPARE team, participants, stakeholders and friends, I am pleased to report that as of August 20 we have enrolled 1,783 prostate cancer patients in COMPPARE, while striving to reach our accrual goal of 900 Pragmatic Proton patients by the end of August. We are working hard to achieve these…
A Message from Dr. Nancy Mendenhall COMPPARE has achieved both a remarkable overall accrual rate and a remarkable accrual rate of minorities. In fact, the study stands to become a model for patient-centric clinical research in the future. Read Dr. Mendenhall’s message. Partner Site…
A Message from Dr. Nancy Mendenhall As we look forward to the normal resumption of our work, we ask you to join us in an effort to encourage all men to get back to having their prostates checked annually in order to detect cancers…
A Message from Dr. Nancy Mendenhall I am thrilled to announce that we have reached 40% of our accrual goal! Our progress is truly astonishing, given the continued challenges COVID-19 has presented us with both globally and locally. Read Dr. Mendenhall’s message.
